{"id":"doi:10.1016/s0140-6736(24)01883-x","kind":"review","title":"Passive anti-amyloid β immunotherapy in Alzheimer's disease—opportunities and challenges","authors":["Michael Thomas Heneka","David Morgan","Frank Jessen"],"author_count":3,"year":2024,"published":"2024-11-01","venue":"The Lancet","cited_by":95,"doi":"10.1016/s0140-6736(24)01883-x","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1016/s0140-6736(24)01883-x","archive_url":"https://space-kitty.com/papers/doi:10.1016/s0140-6736(24)01883-x","updated":null,"pmid":"39549715","pmcid":null,"openalex_id":"W4404365294","pdf_url":null,"abstract":null,"abstract_license":null,"license":null,"is_open_access":false,"retracted":false,"peer_reviewed":null,"categories":["Alzheimer's disease research and treatments"],"details":null,"provenance":"openalex","attribution":"Metadata and citation counts: OpenAlex (CC0).","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}